Clinical Trials
15 trialsNCT05389423 2026-06-01
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07614282 2026-05-29
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
Columbia University
Phase 1 Not yet recruiting
NCT04364178 2026-05-27
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
Phase 1/2 Terminated
NCT03258567 2026-05-22
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03394365 2026-05-22
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT06908096 2026-05-18
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02135042 2026-05-07
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NCT05164094 2026-05-06
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc.
Phase 1/2 Active not recruiting
NCT06682442 2026-05-01
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Phase NA Recruiting
NCT07557602 2026-04-29
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
Vaccine Company, Inc.
Phase 1 Not yet recruiting
NCT04554914 2026-04-27
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT05683834 2026-04-22
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT06119256 2026-04-02
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1 Recruiting
NCT07478952 2026-03-24
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
ModernaTX, Inc.
Phase 1 Recruiting
NCT06256484 2026-03-11
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Phase 1 Terminated